These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38709912)

  • 1. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.
    Fu W; Liu L; Tong S
    Thorac Cancer; 2024 Jun; 15(17):1357-1368. PubMed ID: 38709912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3-mediated m6A modification of CDCA7 mRNA promotes COAD progression.
    Hua M; Zhai X; Chen Y; Yin D
    Pathol Res Pract; 2024 Aug; 260():155437. PubMed ID: 38959625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M6A-induced transcription factor IRF5 contributes to the progression of cervical cancer by upregulating PPP6C.
    Hou PX; Fan Q; Zhang Q; Liu JJ; Wu Q
    Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13868. PubMed ID: 38745265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.
    He P; Liu X; Yu G; Wang Y; Wang S; Liu J; An Y
    Mol Cell Biochem; 2024 Jul; 479(7):1707-1720. PubMed ID: 38822192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circ_0027791 contributes to the growth and immune evasion of hepatocellular carcinoma via the miR-496/programmed cell death ligand 1 axis in an m6A-dependent manner.
    Yu F; Fang P; Fang Y; Chen D
    Environ Toxicol; 2024 Jun; 39(6):3721-3733. PubMed ID: 38546290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
    Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
    Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. m
    Jin D; Guo J; Wu Y; Du J; Yang L; Wang X; Di W; Hu B; An J; Kong L; Pan L; Su G
    J Hematol Oncol; 2019 Dec; 12(1):135. PubMed ID: 31818312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1.
    Song D; Wang Q; Yan Z; Su M; Zhang H; Shi L; Fan Y; Zhang Q; Yang H; Zhang D; Liu Q
    Biol Direct; 2024 Jun; 19(1):44. PubMed ID: 38849910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Berberine inhibits proliferation and induces G0/G1 phase arrest in colorectal cancer cells by downregulating IGF2BP3.
    Zhang Y; Liu X; Yu M; Xu M; Xiao Y; Ma W; Huang L; Li X; Ye X
    Life Sci; 2020 Nov; 260():118413. PubMed ID: 32926933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
    Yi J; Peng F; Zhao J; Gong X
    Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
    Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
    Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6.
    Xu M; Ren L; Fan J; Huang L; Zhou L; Li X; Ye X
    Life Sci; 2022 Feb; 290():120266. PubMed ID: 34968467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
    Chen WW; Qi JW; Hang Y; Wu JX; Zhou XX; Chen JZ; Wang J; Wang HH
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4263-4270. PubMed ID: 32373962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
    Li S; Lu X; Zheng D; Chen W; Li Y; Li F
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3485-3499. PubMed ID: 35907010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
    Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo.
    Zhao Y; Jing Z; Lv J; Zhang Z; Lin J; Cao X; Zhao Z; Liu P; Mao W
    Biomed Pharmacother; 2017 Nov; 95():18-24. PubMed ID: 28826092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
    Ma Z; Li Q; Liu P; Dong W; Zuo Y
    Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL14 contributes to the progression of nasopharyngeal carcinoma through regulating the stability of AOC1 mRNA.
    Hu C; Song S; Zhao S; Xue Z; Zhu X
    Hereditas; 2024 Jul; 161(1):20. PubMed ID: 38956710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.